Table 2.
Pharmacokinetic parameters of HM in rats (mean ± SD, n=5)
| Route | Formulation | Dose (mg/kg) | Cmax(μg/mL) | AUC (μg·h/mL) | BA (%) |
|---|---|---|---|---|---|
| IV | HM | 20 | – | 12.88±1.25 | – |
| HM | 60 | 3.11±0.32 | 9.76±2.34 | 25.25±6.05 | |
| IG | HM-lip | 60 | 1.89±0.43 | 15.08±2.97* | 39.01±7.69** |
| TMC-HM-lip | 60 | 2.67±1.05 | 23.00±4.86* | 59.53±12.58** |
Note:
*
P<0.05,
**
P<0.01, versus HM IG.
Abbreviations: HM, harmine; AUC, area under the concentration–time curve; BA, bioavailability; IV, intravenous; IG, intragastric; HM-lip, harmine liposomes; TMC, N-trimethyl chitosan; TMC-HM-lip, TMC-coated harmine liposomes.